BR0015401A - [(indol-3-yl) -cycloalkyl] -3-substituted azetidines for the treatment of central nervous system disorders - Google Patents
[(indol-3-yl) -cycloalkyl] -3-substituted azetidines for the treatment of central nervous system disordersInfo
- Publication number
- BR0015401A BR0015401A BR0015401-6A BR0015401A BR0015401A BR 0015401 A BR0015401 A BR 0015401A BR 0015401 A BR0015401 A BR 0015401A BR 0015401 A BR0015401 A BR 0015401A
- Authority
- BR
- Brazil
- Prior art keywords
- carbon atoms
- cycloalkyl
- treatment
- nervous system
- central nervous
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Patente de Invenção: "[(INDOL-3-IL)-CICLOALQUIL]-3-AZETIDINAS SUBSTITUìDAS PARA O TRATAMENTO DE DISTúRBIOS DO SISTEMA NERVOSO CENTRAL". Esta invenção refere-se aos novos compostos, composições farmacêuticas e processos de uso dos compostos no tratamento de distúrbios do sistema nervoso central, tais como, ansiedade e depressão, os compostos possuindo a fórmula (I), em que: X é N-R, O, S(O)~ m~ é 0 a 2; n é 0 a 4; Ar é um grupo arila de 6 a 12 átomos de carbono, opcionalmente substituído com 1 a 3 grupos R~ 3~ ou um grupo hetoroarila de 4 a 10 átomos de carbono, opcionalmente substituído com 1 a 3 grupos R~ 3~; R e R~ 2~ são independentemente H, alquila de cadeia linear de 1 a 6 átomos de carbono, alquila ramificada de 3 a 6 átomos de carbono, cicloalquila de 3 a 6 átomos de carbono, alcoxicarbonila de 1 a 6 átomos de carbono, alquilcarbonila de 1 a 6 átomos de carbono, aminocarbonila ou alquilaminocarbonila de 1 a 4 átomos de carbono; R~ 1~ e R~ 3~ são independentemente H, alquila de cadeia linear de 1 a 4 átomos de carbono, alquila ramificada de 3 a 6 átomos de carbono, cicloalquila de 3 a 8 átomos de carbono, halo, grupo alcóxi de 1 a 4 átomos de carbono, haloalquila de 1 a 4 átomos de carbono, OH, nitro, amino, sulfonila, CN, carbóxi, alcoxicarbonila de 1 a 4 átomos de carbono, alquilcarbonila de 1 a 4 átomos de carbono, aminocarbonila ou alquilaminocarbonila de 1 a 4 átomos de carbono; e todas as formas cristalinas ou um sal farmaceuticamente aceitável das mesmas.Invention Patent: "[(INDOL-3-IL) -CYCLOLOQUIL] -3-SUBSTITUTED AZETIDINES FOR THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM". This invention relates to the new compounds, pharmaceutical compositions and processes of use of the compounds in the treatment of disorders of the central nervous system, such as anxiety and depression, the compounds having the formula (I), in which: X is NR, O , S (O) ~ m ~ is 0 to 2; n is 0 to 4; Ar is an aryl group of 6 to 12 carbon atoms, optionally substituted with 1 to 3 R ~ 3 ~ groups or a hetoroaryl group of 4 to 10 carbon atoms, optionally substituted with 1 to 3 R ~ 3 ~ groups; R and R ~ 2 ~ are independently H, straight chain alkyl of 1 to 6 carbon atoms, branched alkyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, alkoxycarbonyl of 1 to 6 carbon atoms, alkylcarbonyl of 1 to 6 carbon atoms, aminocarbonyl or alkylaminocarbonyl of 1 to 4 carbon atoms; R ~ 1 ~ and R ~ 3 ~ are independently H, straight chain alkyl of 1 to 4 carbon atoms, branched alkyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, halo, alkoxy group of 1 to 4 carbon atoms, haloalkyl of 1 to 4 carbon atoms, OH, nitro, amino, sulfonyl, CN, carboxy, alkoxycarbonyl of 1 to 4 carbon atoms, alkylcarbonyl of 1 to 4 carbon atoms, aminocarbonyl or 1-alkylaminocarbonyl to 4 carbon atoms; and all crystalline forms or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43611999A | 1999-11-08 | 1999-11-08 | |
| PCT/US2000/029954 WO2001034598A1 (en) | 1999-11-08 | 2000-10-31 | [(indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0015401A true BR0015401A (en) | 2002-07-02 |
Family
ID=23731187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0015401-6A BR0015401A (en) | 1999-11-08 | 2000-10-31 | [(indol-3-yl) -cycloalkyl] -3-substituted azetidines for the treatment of central nervous system disorders |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1228065A1 (en) |
| JP (1) | JP2003513970A (en) |
| CN (1) | CN1414962A (en) |
| AU (1) | AU1446601A (en) |
| BR (1) | BR0015401A (en) |
| CA (1) | CA2390531A1 (en) |
| MX (1) | MXPA02004555A (en) |
| WO (1) | WO2001034598A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1638939A2 (en) * | 2003-06-24 | 2006-03-29 | Neurosearch A/S | Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| TW200616967A (en) | 2004-06-24 | 2006-06-01 | Smithkline Beecham Corp | Novel indazole carboxamides and their use |
| TW200626142A (en) | 2004-09-21 | 2006-08-01 | Glaxo Group Ltd | Chemical compounds |
| US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
| AR065804A1 (en) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | COMPOSITE OF INDOL CARBOXAMIDE, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND USE OF THIS COMPOUND TO PREPARE A MEDICINAL PRODUCT |
| UY32312A (en) | 2008-12-10 | 2010-06-30 | Janssen Pharmaceutica Nv | 4-AZETIDINIL-1-HETEROARIL-CICLOHEXANOL ANTAGONISTS OF CCR2 |
| WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
| CN102459226B (en) | 2009-04-17 | 2014-09-17 | 詹森药业有限公司 | 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of ccr2 |
| EP2419419B1 (en) | 2009-04-17 | 2014-12-03 | Janssen Pharmaceutica NV | 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 |
| TW201211027A (en) | 2010-06-09 | 2012-03-16 | Janssen Pharmaceutica Nv | Cyclohexyl-azetidinyl antagonists of CCR2 |
| WO2011159854A1 (en) | 2010-06-17 | 2011-12-22 | Janssen Pharmaceutica Nv | Cyclohexyl-azetidinyl antagonists of ccr2 |
| JP6994767B2 (en) * | 2016-06-21 | 2022-01-14 | エックス４ ファーマシューティカルズ， インコーポレイテッド | CXCR4 inhibitor and its use |
| CN116554168A (en) | 2016-06-21 | 2023-08-08 | X4 制药有限公司 | CXCR4 inhibitors and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9401436D0 (en) * | 1994-01-26 | 1994-03-23 | Wellcome Found | Therapeutic heterocyclic compounds |
| ATE223379T1 (en) * | 1998-04-08 | 2002-09-15 | Wyeth Corp | N-ARYLOXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF DEPRESSION |
| CN1166636C (en) * | 1999-01-07 | 2004-09-15 | 惠氏 | Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression |
-
2000
- 2000-10-31 BR BR0015401-6A patent/BR0015401A/en not_active Application Discontinuation
- 2000-10-31 JP JP2001536545A patent/JP2003513970A/en active Pending
- 2000-10-31 EP EP00976731A patent/EP1228065A1/en not_active Withdrawn
- 2000-10-31 CA CA002390531A patent/CA2390531A1/en not_active Abandoned
- 2000-10-31 MX MXPA02004555A patent/MXPA02004555A/en unknown
- 2000-10-31 CN CN00818079A patent/CN1414962A/en active Pending
- 2000-10-31 WO PCT/US2000/029954 patent/WO2001034598A1/en not_active Application Discontinuation
- 2000-10-31 AU AU14466/01A patent/AU1446601A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001034598A1 (en) | 2001-05-17 |
| MXPA02004555A (en) | 2004-09-10 |
| CA2390531A1 (en) | 2001-05-17 |
| AU1446601A (en) | 2001-06-06 |
| CN1414962A (en) | 2003-04-30 |
| JP2003513970A (en) | 2003-04-15 |
| EP1228065A1 (en) | 2002-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0015401A (en) | [(indol-3-yl) -cycloalkyl] -3-substituted azetidines for the treatment of central nervous system disorders | |
| BRPI0407976A (en) | 2,5 and 2,6-substituted tetrahydroisoquinolines for use as 5-ht6 modulators | |
| BR0309875A (en) | methods and compositions for treating peripheral nervous system disorders and novel compounds useful therefor | |
| BRPI0816767B8 (en) | compound 4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-disubstituted 1',3'-ones, pharmaceutical composition and use of same | |
| BRPI0509795A (en) | pharmaceutically acceptable salt or compound thereof, pharmaceutical composition, use of the pharmaceutically acceptable salt or compound thereof, and method for promoting osteogenesis, suppression of bone resorption and / or bone density enhancement | |
| BR0016911A (en) | Benzazole derivatives, use of benzazole derivatives, method to inhibit the expression and / or activity of jnk, method for treating morbid conditions mediated by jnk, pharmaceutical composition containing a benzazole derivative and process for the preparation of a benzazole derivative | |
| BR0213877A (en) | Organic compounds | |
| BRPI0513475A (en) | quinazolin-4-yl-piperidine and cinolin-4-yl-piperidine derivatives as pde10 inhibitors in the treatment of snc disorders | |
| BR0308146A (en) | Compound, pharmaceutical composition, use of a compound, and process for preparing a compound | |
| BRPI0308495B8 (en) | pyridinoyl compound useful for activating 5-ht1f receptors, pharmaceutical formulation, and use of a compound | |
| BRPI0515412A (en) | compound, pharmaceutical composition, and use of a compound or pharmaceutical composition | |
| BRPI0513565A (en) | compound or a pharmaceutically acceptable salt thereof, methods for inhibiting a protein kinase activity, and for treating a patient having a condition that is mediated by protein kinase activity, use of a compound or a pharmaceutically acceptable salt thereof, and, pharmaceutical composition | |
| BR0009297A (en) | Compound, process to produce the same, pharmaceutical composition, method to antagonize degonadotropin releasing hormone in a mammal, and use of a compound | |
| BR0317435A (en) | Pyrimidine Derivatives for the Treatment of Abnormal Cell Growth | |
| BR0007424A (en) | Compound, pharmaceutical composition, method for treating depression in a patient needing it, and process for preparing a compound | |
| BRPI0418099A (en) | compounds, pharmaceutical composition, and use of a compound | |
| BRPI0518360A2 (en) | compound and pharmaceutically acceptable salts thereof, pharmaceutical composition, use of a compound, and process for preparing a compound or pharmaceutically acceptable salt thereof | |
| BRPI0415657A (en) | dihydrobenzofuranyl alkanamine derivatives as 5ht2c agonists | |
| BRPI0507499A (en) | compound or a pharmaceutically acceptable salt or hydrate thereof, pharmaceutical composition, use of the compound, and methods for treating mglur 5-mediated disorders and for inhibiting activation of mglur 5 receptors | |
| BRPI0409211A (en) | compound, pharmaceutical composition, methods for activating 5-ht1f receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal, and, use of a compound | |
| BR0308145A (en) | Compound, pharmaceutical composition, use of a compound, and process for preparing a compound | |
| BR0314488A (en) | Compound, pharmaceutical composition and treatment methods | |
| BRPI0408353A (en) | compound, pharmaceutical composition, methods for the treatment of susceptible neoplasms and for the treatment of viral infections, and, use of a compound | |
| BR0315056A (en) | Compounds having both nicotinically alpha7 agonist activity and 5ht3 antagonist activity for the treatment of central nervous system disorders | |
| BRPI0417520A (en) | Substituted 1h-pyrrolo [3,2-b, 3,2-c, and 2,3-c] pyridine-2-carboxamides and analogues reported as inhibitors of i-epsilon casein kinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |